



ABN 53 075 582 740

ASX ANNOUNCEMENT
16 June 2016

Bionomics Strengthens Board

Australian drug development company Bionomics Limited (ASX:BNO, OTCQX:BNOEF) has appointed David Wilson and Peter Turner as non-executive directors.

These appointments follow a shareholder consultation process and the Company's governance process commenced in the first quarter of 2016 to review the Company's Board structure and strengthen the Board in areas of finance related to investment banking and in life science drug development, manufacturing and commercialisation.

Mr Wilson is currently the Executive Chairman and CEO of WG Partners, a specialist global life sciences corporate advisory firm based in London. Mr Wilson brings over 30 years' experience in global investment banking with specialist knowledge in life sciences financing and M+A. In the last four years WG Partners has acted for approximately 40 listed clients in the sector in UK, US, Australia and throughout Continental Europe

Prior to WG Partners, Mr Wilson worked for Piper Jaffray, a leading NYSE listed Investment Banking Group where he served as Head of European Investment Banking and then as Chief Executive Officer of Piper Jaffray Ltd. He was also on the Group Leadership Team and served as Chairman of Piper Jaffray's Global Healthcare Group. Mr Wilson has also formerly held the role of Joint Head of UK Investment Banking Group at ING Barings, Director of Investment Banking at Deutsche Bank AG (UK), and Head of Small Companies Corporate Broking at UBS. Mr Wilson holds a Bachelor of Arts (Classics) from Cambridge University. Mr Wilson is based in the UK and travels regularly to Australia as part of WG Partners' Australian operations based in Sydney.

Mr Turner is an experienced senior international executive with a long history in the life sciences industry, first as a biochemist and then in management roles with CSL Limited. Mr Turner has senior experience in commercialisation initiatives, R&D program management and risk management at an international level. Mr Turner was previously the President of CSL Behring Group and Chief Operating Officer of CSL Limited. In his role as COO of CSL Mr Turner was based in Philadelphia with a portfolio covering over 10,000 employees with an international manufacturing capability across 22 countries and a turnover of US\$3.4 billion. He additionally oversaw 13 new product launches into the US and European healthcare markets as part of CSL's highly successful R&D programs. He was formerly an executive director of CSL Limited and is currently a non-executive director of Virtus Healthcare Ltd and non-executive Chair of NPS Medicinewise. Mr Turner holds a Bachelor of Science (Biochemistry/Microbiology/Chemistry) from the University of Melbourne, an MBA from RMIT, and is a Graduate Member of the Australian Institute of Company Directors. Since his retirement from CSL, Mr Turner has resided in Melbourne.

A Shareholder Working Group comprised of Platinum Investment Management's Bianca Ogden, Ausbil Investment Management's Paul Xiradis and Mans Carlsson-Sweeny, and Private Portfolio Managers' Hugh MacNally, along with Bionomics' non-executive director and Chair of Bionomics' Nominations Committee Dr Errol De Souza assisted the Company in providing a transparent and structured Board recruitment process.

Bionomics' Chairman Graeme Kaufman said, "Following a thorough review and extensive shareholder consultation process, which involved a review of many high calibre board candidates, we welcome David Wilson and Peter Turner to the Bionomics' Board. They will enhance the expanded Board's skills base in investment, finance and drug development. We would also like to take this opportunity to thank the Shareholder Working Group for their time and efforts in guiding the selection of our new directors".

The Shareholder Working Group said "We are pleased to have been able to assist Bionomics in making these important appointments to the Board. David and Peter bring a wealth of experience which will guide Bionomics as it builds its global business. The process has been robust and the views of shareholders have been carefully considered".

With these appointments the Bionomics board will expand from five to seven members.

FOR FURTHER INFORMATION PLEASE CONTACT:

Australia

Monsoon Communications
Rudi Michelson
+613 9620 3333
rudim@monsoon.com.au

US

Stern IR, Inc.
Beth Del Giacco
+1 212 362 1200
beth@sternir.com

About Bionomics Limited

Bionomics (ASX: BNO) is a global, clinical stage biopharmaceutical company leveraging its proprietary platform technologies to discover and develop a deep pipeline of best in class, novel drug candidates focused on the treatment of serious central nervous system disorders and on the treatment of cancer. Bionomics' lead drug candidate BNC210, currently in Phase 2 for the treatment of generalized anxiety disorder, is a novel, proprietary negative allosteric modulator of the alpha-7 ($\alpha 7$) nicotinic acetylcholine receptor. The Company is also developing BNC101, its lead humanized monoclonal antibody targeting a key receptor on cancer stem cells that is overexpressed in metastatic colorectal cancer, metastatic pancreatic cancer and many other solid tumours; BNC101 entered clinical trials in the first quarter of 2016. Bionomics has strategic partnerships with Merck & Co., Inc (known as MSD outside the United States and Canada) in pain and cognition.

www.bionomics.com.au

Factors Affecting Future Performance

This announcement contains "forward-looking" statements within the meaning of the United States' Private Securities Litigation Reform Act of 1995. Any statements contained in this announcement that relate to prospective events or developments, including, without limitation, statements made regarding Bionomics' drug candidates (including BNC210 and BNC101), its licensing agreements with Merck & Co. and any milestone or royalty payments thereunder, drug discovery programs, ongoing and future clinical trials, and timing of the receipt of clinical data for our drug candidates are deemed to be forward-looking statements. Words such as "believes," "anticipates," "plans," "expects," "projects," "forecasts," "will" and similar expressions are intended to identify forward-looking statements.

There are a number of important factors that could cause actual results or events to differ materially from those indicated by these forward-looking statements, including unexpected safety or efficacy data, unexpected side effects observed in clinical trials, risks related to our available funds or existing funding arrangements, our failure to introduce new drug candidates or platform technologies or obtain regulatory approvals in a timely manner or at all, regulatory changes, inability to protect our intellectual property, risks related to our international operations, our inability to integrate acquired businesses and

technologies into our existing business and to our competitive advantage, as well as other factors. Results of studies performed on our drug candidates and competitors' drugs and drug candidates may vary from those reported when tested in different settings.

Subject to the requirements of any applicable legislation or the listing rules of any stock exchange on which our securities are quoted, we disclaim any intention or obligation to update any forward-looking statements as a result of developments occurring after the date of this announcement.